ARMP Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 27.96%, SMA50 51.24%, SMA200 150.42%). The stock’s 14-day RSI is 70.33 (overbought), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.72% below its high and over 1105.88% above its low. Average 10-day trading volume of 145.10 thousand shares is slightly above the 3-month average of 117.36 thousand, indicating heightened recent market interest.

Armata Pharmaceuticals, Inc. generated EPS of -$1.32 over the past year. Five-year average earnings growth is 26.8%. Wall Street analysts project EPS growth of -12.29% annually over the next five years. The latest quarter delivered EPS of -$3.16. The next quarter is forecast at -$0.28. Next year's EPS is expected at $53.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 210.56% upside. The low target suggests 210.56% downside. The mean target is $15.00. This offers 210.56% upside. Armata Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by 731.58%. The prior quarter beat by 731.58%. Over the last six quarters, Apple has recorded several small beats. These include -47.37% in May 14, 2025.

Armata Pharmaceuticals, Inc. has 36.71 million shares outstanding. The public float is 11.55 million shares, elevated short interest at 1.92% of float. This equals 206.87 thousand shares. The short ratio is 3.04 days. Institutional investors hold 6.75% of the float. Insiders own 69.14%. BIOGEN IDEC INC holds 11.70 million shares, Innoviva Strategic Opportunities LLC has 2.69 million shares and KIRK RANDAL J has 674.17 thousand shares.

Armata Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$10.96. This means the shares are trading below this model’s fair value.

Armata Pharmaceuticals, Inc. (AMEX:ARMP) closed at $4.83 USD, losing -$0.27 (-5.29%) from the previous close of $5.10. The stock is currently mid-range between its 52-week high and low $2.14 and $16.34. With a market capitalization of about $177.31 million, Armata Pharmaceuticals, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.27). Key stats such as the average daily volume over the past year has been around 111.81 thousand shares, trading with heavier-than-usual volume. Headquartered in Marina del Rey, CA, Armata Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Deborah L. Birx, the company employs approximately 60 people and listed since May 20, 1994. Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics.

Armata Pharmaceuticals, Inc. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 60.81 and a price-to-book ratio of -0.57 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.35, also above market averages.

Our AI price prediction model suggests that Armata Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.63%, with price expected at $4.22 by July 22, 2026, within a range of $3.90 to $4.55 3-Month Outlook: Projected fall of -18.84%, reaching $3.92 by October 06, 2026, with a range of $3.73 to $4.15. 1-Year Outlook: Projected gain of 250.1%, with price at $16.91 by July 08, 2027, within a range of $16.88 to $17.30.

Armata Pharmaceuticals, Inc. (AMEX:ARMP) shares are flat -5.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Armata Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.67, suggesting 79.5% upside. Our AI forecast model points to short-term weakness (-12.63% over two weeks), a medium-term fall (-18.84% over three months), and a longer-term gain (250.1% over one year), with expected trading ranges indicating moderate volatility.